Ultime notizie per Cannabis Suisse (OTC:CSUI) Azioni

Cannabis Suisse Corp is engaged in the rental of commercial office and industrial space.

CANNABIS SUISSE CORP by Cannabis Suisse Corp.

Cannabis Suisse Corp

ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.77 by 41.56 percent. This is a 68.75 percent decrease over earnings of $1.44 per share from the same period last year. The company reported quarterly sales of $702.04 million which missed the analyst consensus estimate of $714.92 million by 1.80 percent. This is a 2.20 percent increase over sales of $686.92 million the same period last year.

Earnings

Earnings Misses

News

MODV

ModivCare Q3 Adj $0.45 Misses $0.77 Estimate, Sales $702.04M Miss $714.92M Estimate

2024 Financial Guidance
The company now expects 2024 Adjusted EBITDA between $7 billion and $7.150 billion, which is an increase to the midpoint of guidance by $125 million. In addition, the company continues to expect 2024 growth capex between $1.45 billion and $1.75 billion and maintenance capex between $1.1 billion and $1.3 billion, which includes capital of $350 million for emissions reduction and modernization initiatives. For 2025, the company continues to expect Adjusted EBITDA between $7.2 billion and $7.6 billion with growth capex between $1.65 billion and $1.95 billion and maintenance capex between $750 million and $850 million, which includes capital of $100 million for emissions reduction and modernization initiatives. Williams anticipates a leverage ratio midpoint for 2024 of 3.80x and an increase in the dividend by 6.1% on an annualized basis to $1.90 in 2024 from $1.79 in 2023.

Guidance

Williams Sees FY24 Adj. EBITDA $7B-$7.15B

Outlook
The company is providing the following guidance for fiscal 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">$1.98 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net Income</td>
<td colspan="1" rowspan="1">$624 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP EPS</td>
<td colspan="1" rowspan="1">$25.05</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net Income</td>
<td colspan="1" rowspan="1">$712 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP EPS</td>
<td colspan="1" rowspan="1">$28.58</td>
</tr>
</tbody>
</table>
</figure>
The Non-GAAP financial measures are described in the financial table captioned "Reconciliation of Non-GAAP Guidance."

FICO

Fair Isaac Corp Sees FY25 EPS $28.58 Vs $29.75 Est.; Revenue $1.98B Vs $1.98B Est.

<a href="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7" title="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7">https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7</a>

Politics

General

LIVE: Kamala Harris delivers concession speech - AP

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) is looking for Q4 Adj EPS of $0.48-0.51 vs $0.53 analyst estimate. seessales of $211.000 million-213.000 million vs $211.77 million estimate.

Rapid7 Sees Q4 Adj EPS $0.48-0.51 vs $0.53 Est; Sees Sales $211.000M-213.000M vs $211.77M Est

Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. The company reported quarterly sales of $26.082 million which missed the analyst consensus estimate of $29.843 million by 12.60 percent. This is a 147.62 percent increase over sales of $10.533 million the same period last year.

Earnings Beats

RXRX

Recursion Pharmaceuticals Q3 2024 GAAP EPS $(0.34) Beats $(0.37) Estimate, Sales $26.082M Miss $29.843M Estimate

TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) lowers FY2024 Adj EPS guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 analyst estimate. Affirms FY2024 sales outlook from $2.21 billion-2.26 billion to $2.21 billion-2.26 billion vs $2.22 billion estimate.

TTEC

TTEC Holdings Lowers FY2024 Adj EPS Guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 Est; Affirms FY2024 Sales Guidance from $2.21B-2.26B to $2.21B-2.26B vs $2.22B Est

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) raises FY2024 Adj EPS guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 analyst estimate. Raises FY2024 sales outlook from $833.00 million-837.00 million to $839.00 million-841.00 million vs $834.13 million estimate.

Rapid7 Raises FY2024 Adj EPS Guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 Est; Raises FY2024 Sales Guidance from $833.00M-837.00M to $839.00M-841.00M vs $834.13M Est

Permian Resources Q3 Oil Sales $1.099B

Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) reported quarterly sales of $101.51 million which beat the analyst consensus estimate of $82.90 million by 22.44 percent. This is a 4.48 percent decrease over sales of $106.27 million the same period last year.

BRDG

Bridge Investment Group Q3 Sales $101.51M Beat $82.90M Estimate

CLOV

Clover Health Sees FY24 Adj. EBITDA Profitability $55M-$65M

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.71 by 15.2 percent. This is a 56.35 percent increase over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $593.74 million which missed the analyst consensus estimate of $613.63 million by 3.24 percent. This is a 5.96 percent increase over sales of $560.35 million the same period last year.

STRL

Sterling Infrastructure Q3 EPS $1.97 Beats $1.71 Estimate, Sales $593.74M Miss $613.63M Estimate

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. The company reported quarterly sales of $122.751 million which missed the analyst consensus estimate of $125.853 million by 2.47 percent. This is a 3.99 percent decrease over sales of $127.854 million the same period last year.

NDLS

Noodles Q3 2024 Adj. EPS $(0.12) Misses $(0.06) Estimate, Sales $122.751M Miss $125.853M Estimate

Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $403.500 million which beat the analyst consensus estimate of $392.440 million by 2.82 percent. This is a 14.34 percent increase over sales of $352.900 million the same period last year.

Crane NXT Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $403.500M Beat $392.440M Estimate

Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent.

Brookdale Senior Living Q3 2024 Adj. EPS $(0.22) Misses $(0.17) Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

VCYT

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

CLNE

Clean Energy Fuels Sees FY24 Adj. EBITDA $62M-$72M

VIZIO Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZIO#NYSE">VZIO</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.02) by 105 percent. The company reported quarterly sales of $444.70 million which beat the analyst consensus estimate of $443.80 million by 0.20 percent. This is a 4.34 percent increase over sales of $426.20 million the same period last year.

VZIO

VIZIO Holding Q3 2024 GAAP EPS $0.00 Beats $(0.02) Estimate, Sales $444.70M Beat $443.80M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) raises FY2025 sales outlook from $715.00 million-735.00 million to $737.00 million-739.00 million.

RAMP

LiveRamp Holdings Raises FY2025 Sales Guidance from $715.00M-735.00M to $737.00M-739.00M

Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $330.99 million which missed the analyst consensus estimate of $346.28 million by 4.42 percent. This is a 8.16 percent increase over sales of $306.03 million the same period last year.

Comments

Cannabis Suisse

Notizie

Ultime notizie per Cannabis Suisse (OTC:CSUI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO